High-throughput Toxicology Assay
The High-Throughput Toxicology Assay evaluates compound effects on the viability of adult human iPSC cardiomyocytes in a 96 well plate format.
The potential for cardiotoxicity is a major consideration in the design and development of therapeutic agents. Currently used preclinical cardiomyocyte models, such as in vivo animal testing or primary cell testing, are plagued by supply limitations, questionable relevance, and inconsistency with respect to genetic background. Adult human iPSC cardiomyocytes are now manufactured through uniform protocols and offer a uniform genetic background for consistent results. When coupled with electrophysiology assays, a cardiac safety ratio for a new therapeutic agent can be determined.

References
- Schweikart, K., Guo, L., Shuler, Z., Abrams, R., Chiao, E.T., Kolaja, K.L., et al. (2013). The effects of jaspamide on human cardiomyocyte function and cardiac ion channel activity. Toxicology In Vitro, 27(2), 745-751.
- Reynolds, J.G., Geretti, E., Hendriks, B.S., Lee, H., Leonard, S.C., Klinz, S.G., et al. (2012). HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity. Toxicology and Applied Pharmacology, 262(1), 1-10.
Request A No Obligation Quote
To discuss a project and to receive a quote, please call 314-485-5210 or email us at sales@mayflowerbio.com and one of our specialists will be in touch.

- New: Coronavirus Research Tools
- Ebola Antibodies and Antigens
- LentiBOOST pharma grade non-GMP material
- Multiplexed bead-based immunoassays
- C-Slide - The New Name for Countess Slides
- New: PODS™ - Slow Release Growth Factors
- New: C80EZ Cryopreservation Media - -80C Safe Cell Storage
- RNA Extraction Kit from Fresh Cells
